Summary:
A phase III, multinational, randomized, double-blind, placebo-controlled, parallel-group study to investigate the clinical efficacy and safety of DIAPEP277 in newly diagnosed type 1 diabetes subjects.
Qualified Participants Must:
• Be 20-45 years of age
• Be diagnosed with type 1 diabetes for up to 5 months
Qualified Participants May Receive:
Eligible participants will receive up to $325 for time and travel.